Kane Biotech to Release Third Quarter 2021 Financial Results on November 16 – Conference Call to Follow

WINNIPEG, Manitoba, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its third quarter 2021 financial results after market close on Thursday, November 16, 2021.

Kane Biotech management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.

Third Quarter2021ResultsConferenceCallDetails:

Replay: 1-404-537-3406
Conference ID: 6379645

Webcast URL: https://edge.media-server.com/mmc/p/ubu6dk8i

The call will also be broadcast live and archived on the Company’s website at www.kanebiotech.comunder “News/Events” in the Investors section.

AboutKaneBiotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (52 patents and patents pending, trade secrets and trademarks) and products developed by the Company’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactive+®, DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol “KNE” and on the OTCQB Venture Market under the symbol “KNBIF”.

Formoreinformation,kanebiotech.com,or:

NeitherTSXVentureExchangenoritsRegulationServicesProvider(asthattermisdefinedin policies of the TSX Venture Exchange) accepts responsibility for the adequacy oraccuracyofthisrelease.

CautionRegardingForward-LookingInformation
This press release contains certain statements regarding Kane Biotech Inc. that constituteforward-looking information under applicable securities law. These statements reflectmanagement’s current beliefs and are based on information currently available tomanagement. Certain material factors or assumptions are applied in making forward-lookingstatements, and actual results may differ materially from those expressed or implied in suchstatements. These risks and uncertainties include, but are not limited to, risks relating to theCompany’s:(a)financialcondition,includinglackofsignificantrevenuestodateandrelianceon equity and other financing; (b) business, including its early stage of development,government regulation, market acceptance for its products, rapid technological change anddependence on key personnel; (c) intellectual property including the ability of the Companyto protect its intellectual property and dependence on its strategic partners; and (d) capitalstructure, including its lack of dividends on its common shares, volatility of the market priceof its common shares and public company costs. Further information about these and otherrisks and uncertainties can be found in the disclosure documents filed by the Company withapplicable securities regulatory authorities, available at www.sedar.com. The Companycautionsthattheforegoinglistoffactorsthatmayaffectfutureresultsisnotexhaustive.

Source: Kane Biotech Inc.